Armata Pharmaceuticals, Inc. (ARMP)

[someconcerns]

Seel,

My thinking is that it WILL allow a greater variety of marketing arrangements and (maybe) might not preclude some sort of distribution thru XON. At least as long as their (XON's) feelings weren't hurt too badly. This business could still be quite profitable for XON once we get closer to commercializing the first phage.

The SP drop today is - IMHO - overdone and should see some bargain hunters. Maybe including me.

I found the news earlier this week of the phages being able to dramatically cut the concentration of bacteria commonly affecting CF patients VERY promising.

Go $APHB.

Steve